THURSDAY, June 5, 2025 (HealthDay News) — More American teenagers now use the weight-loss drug Wegovy, as doctors and ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Chart: The Economist Lilly has also been quicker to expand production in response to soaring demand. Wegovy was on America’s official shortage list until February; Lilly had sorted out its ...

It said lower prices for Zepbound trimmed revenue in the quarter, but that demand remained ... PBMs," he said. The chart shows U.S. prescriptions for Novo Nordisk's Wegovy and Eli Lilly's Zepbound ...

The chart I drew up below showcases just how expensive Hims products were, before this morning’s partnership, when compared to the competition. Hims can sell Wegovy to its existing customer base ...

"Demand for the medications Mounjaro, Zepbound, Ozempic, and Wegovy (GLP-1 drugs) has skyrocketed, but supply shortages and high costs have created opportunities for wrongdoers to cash in and ...

The long-running U.S. shortage of Novo Nordisk's blockbuster weight loss injection Wegovy and diabetes treatment ... in the U.S. since 2022 after demand skyrocketed. That has forced Novo Nordisk ...

By offering a more cost-effective alternative to Wegovy, Dr. Reddy’s aims to improve access to obesity treatments in India, where the demand for ... share interesting charts, data points and ...

The Swiss drugmaker is betting that the existing generation of GLP-1 weight-loss drugs will stay in demand — and that generics will ... One in Three Novo’s Wegovy, the version of the drug sold for ...